Email this article Targeted therapy in the treatment of HER-2 positive breast cancer with brain metastases
- Authors: Naskhletashvili D.R.1, Roshchina K.E.1, Gorbunova V.A.1, Gasparyan T.G.1, Bychkov M.B.1, Bekyashev A.H.1, Karakhan V.B.1, Moskvina E.A.1, Aleshin V.A.1, Belov D.M.1, Mitrofanov A.A.1, Prozorenko E.V.1, Pogosova A.A.1
-
Affiliations:
- National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
- Issue: Vol 25, No 4 (2020)
- Pages: 146-153
- Section: Clinical investigations
- URL: https://rjonco.com/1028-9984/article/view/59340
- DOI: https://doi.org/10.17816/1028-9984-2020-25-4-146-153
- ID: 59340
Cite item
Open Access
Access granted
Abstract
Metastatic damage to the brain is a frequent manifestation in tumors of various localizations, including breast cancer. Until recently, systemic therapy of metastatic brain damage was of limited use; however, with the advent of targeted drugs that are better understood in terms of the specific molecular targets and biological characteristics of metastases, it is now possible to improve treatment results. In an analysis of the results of studies on the problem of metastasis of breast cancer in the brain, a comparison of the use of various targeted drugs in the treatment of metastatic HER2 + breast cancer is presented. The results of a comparison of the degrees of effectiveness of targeted drugs, both in monotherapy and in combination with chemotherapy, were obtained and analyzed.
Keywords
Full Text
About the authors
David R. Naskhletashvili
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Author for correspondence.
Email: nas-david@yandex.ru
ORCID iD: 0000-0002-4218-9652
MD, PhD, senior researcher, N.N. Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowK. E. Roshchina
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0002-6792-967X
Russian Federation
V. A. Gorbunova
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
Russian Federation
T. G. Gasparyan
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0003-0194-7645
Russian Federation
M. B. Bychkov
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
Russian Federation
A. H. Bekyashev
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0002-4160-9598
Russian Federation
V. B. Karakhan
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0001-6325-716X
Russian Federation
E. A. Moskvina
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
Russian Federation
V. A. Aleshin
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0003-1850-5595
Russian Federation
D. M. Belov
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0003-1766-0032
Russian Federation
A. A. Mitrofanov
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0002-4125-7342
Russian Federation
E. V. Prozorenko
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
ORCID iD: 0000-0001-8880-1758
Russian Federation
A. A. Pogosova
National Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of Russia
Email: nas-david@yandex.ru
Russian Federation
References
- Chissov VI, Starinskiy VV, Petrova GV. Malignant neoplasms in Russia in 2010. Moscow: FGBU “MNIOI im. P.A. Gertsena”; 2012. (In Russ).
- Kennecke H, Yerushalmi R, Woods R, Chon U, Cheang M,Voduc D, et al. Metastatic Behavior of Breast Cancer Subtypes. J Clin Oncol. 2010;28(20):3271–3277. doi: 10.1200/JCO.2009.25.9820.
- Semiglazov VF, Paltuev RM, Semiglazov VV, et al. Early breast cancer: the prognostic value of biological subtypes. Analiz nakopitel’noy bazy dannykh FGBU «NII onkologii im. N.N. Petrova» Minzdravsotsrazvitiya. 2012;1–112. doi: 10.18027/2224-5057-2012-2-12-18. (In Russ).
- Bit-Sava EM, Belogurova MB. Hereditary breast cancer. Sibirskiy onkologicheskiy zhurnal. 2013;55(1):1–16. (In Russ).
- Plotnikova VE, Nepomnyashchaya EM, Grigorov SV. Risk factors for metastatic brain lesions in breast cancer. Nauchnye vedomosti BelGU. Meditsina. Farmatsiya. 2013;154(11):1–154.(In Russ).
- Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17). doi: 10.1200/JCO.2004.01.175
- Demircioglu F, Demirci U, Akmansu M. Lymphnode ratio assessment of brain metastasis in early breast cancer cases. Asian Pacific J Cancer Prev. 2013;14(3):1665–1667. doi: 10.7314/APJCP.2013.14.3.1665.
- Balkonov AS, Petrushkina NN. Features of metastasis to the brain in patients with luminal subtype of breast cancer. Al’manakh klinicheskoy meditsiny. 2016;44(5):635–639. doi: 10.18786/2072-0505-2016-44-5-635-639. (In Russ.)
- Gabos Z, SinhaR, Hanson J, Chauhan N, Hugh J, Mackey Bassam A.R.J. Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer. Journal of Clinical Oncology. 2006;24(36):5658–5663. DOI: 10200/JCO.2006.07.0250.
- Adam M, Brufsky, et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from regist HER. Clin Cancer Res. 2011;17(14):4834–4843. doi: 10.1158/1078-0432.CCR-10-2962.
- Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology. 2006;17:935–944. doi: 10.1093/annonc/mdl064.
- Cortés J, Rugo HS, Awada A, Twelves C. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017;165:329–341. doi: 10.1007/s10549-017-4304-7.
- Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist. 2002;7(5):410–417. doi: 10.1634/theoncologist.7-5-410.
- Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Cancer. 2004;91(4):639–643. doi: 10.1038/sj.bjc.6601970.
- Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977. doi: 10.1002/cncr.11436.
- Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first-line chemotherapy for patients with HER2-enhanced metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of clinical oncology. 2011;29(2):149–156. doi: 10.1200/jco.2010.28.6450.
- Harbeck N, Heinemann V, Loibl S, Untchd M. Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel). 2008;(3 Suppl 1):7–12. doi: 10.1159/000119744.
- Bachelot T, Romieu G, Campone M, Diéras V, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi: 10.1016/S1470
- Naskhletashvili DR, Gorbunova VA, Moskvina EA. Chemotherapy and targeted therapy of breast cancer patients with metastatic brain lesions. Opukholi golovy i shei. 2014;(4):17–21. (In Russ).
- Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER-2-positive metastatic breast cancer. Clin. Cancer Res. 2014;20(17):4436–4441. doi: 10.1158/1078-0432.CCR-14-0012.
- Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–119. doi: 10.1093/annonc/mdu486.
- Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921–56931. doi: 10.18632/oncotarget.18176.
- Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. doi: 10.1016/S1470-2045(15)00551-3
- Awada A, Colomer R, Inoue K, et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1557–1564. doi: 10.1001/jamaoncol.2016.0237.
- Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Clin. Oncol. 2016;34(9):945–952. doi: 10.1200/JCO.2015.63.0343.
- Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Clin Oncol. 2014;32(32):3626–3633. doi: 10.1200/JCO.2014.56.3809.
Supplementary files
